|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Securities available-for-sale, at fair value | ||||||||||||||||||||
| Securities held-to-maturity, at amortized cost | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Loans and leases receivable, net of allowance for credit losses of $32,799 and $31,275, respectively | ||||||||||||||||||||
| Loans and leases receivable, net of allowance for credit losses of $37,393 and $35,877, respectively | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Repossessed assets | ||||||||||||||||||||
| Right-of-use assets, net | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Federal Home Loan Bank stock, at cost | ||||||||||||||||||||
| Goodwill and other intangible assets | ||||||||||||||||||||
| Derivatives | ||||||||||||||||||||
| Accrued interest receivable and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Federal Home Loan Bank advances and other borrowings | ||||||||||||||||||||
| Lease liabilities | ||||||||||||||||||||
| Derivatives | ||||||||||||||||||||
| Accrued interest payable and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Preferred Stock, Shares Outstanding | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock, $0.01 par value, 2,500,000 shares authorized, 12,500 shares of 7% non-cumulative perpetual preferred stock, Series A, outstanding at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock, $0.01 par value, 25,000,000 shares authorized, 9,565,153 and 9,493,274 shares issued, 8,368,320 and 8,325,376 shares outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock, 1,196,833 and 1,167,898 shares at June 30, 2026 and December 31, 2025, respectively, at cost | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
